Anti-VEGF Use in Ophthalmology

Jay S. Duker, MD, is Professor and Chairman of Ophthalmology at the Tufts Medical Center and Tufts University School of Medicine and Director of the New England Eye Center in Boston, Massachusetts. Dr. Duker graduated from Jefferson Medical College and completed ophthalmology and retina training at the Wills Eye Hospital. His research and clinical interests are focused on the posterior segment ranging from macular degeneration, diabetic retinopathy, and retinal vascular diseases, as well as uveitis and intraocular tumors. He has published more than 280 journal articles and has been lead editor on six books and dozens of book chapters. Dr. Duker is the co-editor of the International Journal of Retina and Vitreous.Michelle C. Liang, MD, is Assistant Professor of Ophthalmology at the Tufts University School of Medicine and a vitreoretinal specialist at the New England Eye Center in Boston, Massachusetts. She graduated with honors from Johns Hopkins University with a degree in Biology and earned her medical degree from the University at Buffalo School of Medicine and Biomedical Sciences. She performed her residency in ophthalmology at the New England Eye Center at Tufts Medical Center and went on to complete a vitreoretinal surgery fellowship at the New England Eye Center and Ophthalmic Consultants of Boston.Dr. Liang has authored numerous scientific papers and book chapters and has presented at several national meetings. She treats all conditions of the retina and vitreous, including macular degeneration, vitreomacular disorders, diabetic retinopathy, retinal vascular disorders, retinal detachment, and cataract complications. Her research interests include retinal imaging and new therapies for macular degeneration, diabetic macular edema, and other diseases. Dr. Liang is a board-certified member of the American Board of Ophthalmology and a member of the American Academy of Ophthalmology and American Society of Retinal Specialists.

• Dedication About the Editors Contributing AuthorsIntroduction Section I Overview of Anti-Vascular Endothelial Growth Factor Agents Chapter 1 Vascular Endothelial Growth Factor: Background and HistoryAnthony Joseph, MD and Ehsan Rahimy, MD Chapter 2 Development of Anti-Vascular Endothelial Growth Factor AgentsMaya H. Maloney, MD and Sophie J. Bakri, MD Chapter 3 Available Anti-Vascular Endothelial Growth Factor AgentsAngeline Mariani Derham, MD and David M. Brown, MD, FACS Chapter 4 Agents Under Study Ehsan Rahimy, MD; Elham Rahimy, BS; and Anthony Joseph, MD Chapter 5 Intravitreal DeliveryNora Muakkassa, MD; Kendra Klein, MD; and Elias Reichel, MD Chapter 6 Sustained Delivery Options Under StudyMichael N. Cohen, MD; Chirag P. Shah, MD, MPH; and Jeffrey S. Heier, MD Section II Use of Anti-Vascular Endothelial Growth Factor Agents in Clinical Practice Chapter 7 Neovascular Age-Related Macular DegenerationMichael D. Lewen, MD and Andre J. Witkin, MD Chapter 8 Choroidal Neovascularization, Not Age-Related Macular DegenerationDarin R. Goldman, MD Chapter 9 Diabetic Macular EdemaEmily D. Cole, BS; Eduardo A. Novais MD; and Nadia K. Waheed, MD, MPH Chapter 10 Proliferative Diabetic RetinopathySabin Dang, MD and Chirag P. Shah, MD, MPH Chapter 11 Retinal Vein OcclusionShilpa Desai, MD and Caroline R. Baumal, MD Chapter 12 UveitisLana M. Rifkin, MD Chapter 13 Retinopathy of PrematurityNikisha A. Kothari, MD and Audina M. Berrocal, MD Chapter 14 Miscellaneous Retinal and Choroidal DiseasesMichael D. Tibbetts, MD Chapter 15 Neovascular GlaucomaManik Goel, MD and Joel S. Schuman, MD, FACS Chapter 16 Glaucoma SurgeryJessica J. Moon, MD and Cynthia Mattox, MD Chapter 17 Anterior Segment DiseasesAlessandro Abbouda, MD; Bijan Khaksari, BA; and Pedram Hamrah, MD, FRCSFinancial Disclosures Index